Ubs Asset Management Americas Inc Uro Gen Pharma Ltd. Transaction History

Ubs Asset Management Americas Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.12 - $8.74 $114,688 - $195,776	-22,400 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$18.81 - $26.42 $62,054 - $87,159	3,299 Added 17.27%	22,400 $432,000
Q2 2020 Aug 14, 2020	SELL	$16.5 - $29.7 $44,550 - $80,190	-2,700 Reduced 12.38%	19,101 $498,000
Q1 2020 May 15, 2020	BUY	$13.68 - $34.6 $73,872 - $186,840	5,400 Added 32.92%	21,801 $388,000
Q4 2019 Feb 14, 2020	BUY	$21.11 - $34.86 $346,225 - $571,738	16,401 New	16,401 $547,000

Q3 2019 Nov 14, 2019	SELL	$23.83 - $36.44 $145,363 - $222,284	-6,100 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$35.47 - $54.55 $216,367 - $332,755	6,100 New	6,100 $0

113

24M

46.9K

44.3K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $373M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.